SG10201501936PA - Polymorphic forms st-246 and methods of preparation - Google Patents

Polymorphic forms st-246 and methods of preparation

Info

Publication number
SG10201501936PA
SG10201501936PA SG10201501936PA SG10201501936PA SG10201501936PA SG 10201501936P A SG10201501936P A SG 10201501936PA SG 10201501936P A SG10201501936P A SG 10201501936PA SG 10201501936P A SG10201501936P A SG 10201501936PA SG 10201501936P A SG10201501936P A SG 10201501936PA
Authority
SG
Singapore
Prior art keywords
preparation
methods
polymorphic forms
polymorphic
forms
Prior art date
Application number
SG10201501936PA
Other languages
English (en)
Inventor
Shanthakumar R Tyavanagimatt
Melialani A C L Stone
William C Weimers
Dylan Nelson
Tove C Bolken
Dennis E Hruby
Michael H O'neill
Gary Sweetapple
Kelley A Mccloughan
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of SG10201501936PA publication Critical patent/SG10201501936PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/724,7-Endo-alkylene-iso-indoles
    • C07D209/764,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
SG10201501936PA 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation SG10201501936PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31674710P 2010-03-23 2010-03-23
US37303110P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
SG10201501936PA true SG10201501936PA (en) 2015-05-28

Family

ID=44656766

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201501936PA SG10201501936PA (en) 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation
SG2012070322A SG184201A1 (en) 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012070322A SG184201A1 (en) 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation

Country Status (20)

Country Link
US (6) US9339466B2 (zh)
EP (1) EP2549871B1 (zh)
JP (3) JP6018041B2 (zh)
KR (6) KR20160028489A (zh)
CN (4) CN103068232B (zh)
AP (1) AP3221A (zh)
AU (1) AU2011232551B2 (zh)
BR (1) BR112012023743B1 (zh)
CA (2) CA3030671A1 (zh)
CL (1) CL2012002621A1 (zh)
DK (1) DK2549871T3 (zh)
FR (1) FR22C1023I2 (zh)
IL (4) IL221991B (zh)
MX (1) MX361428B (zh)
NZ (1) NZ602578A (zh)
PE (2) PE20130212A1 (zh)
RU (2) RU2015146899A (zh)
SG (2) SG10201501936PA (zh)
WO (1) WO2011119698A1 (zh)
ZA (1) ZA201207141B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
DK2549871T3 (en) * 2010-03-23 2018-12-10 Siga Tech Inc Polymorphic form ST-246 and processes for its preparation
CA2882506C (en) * 2012-08-16 2020-10-20 Siga Technologies, Inc. Methods of preparing tecovirimat
EP3763702B1 (en) * 2013-07-19 2023-12-13 Siga Technologies, Inc. Preparation of amorphous tecovirimat dispersions
WO2015077143A1 (en) 2013-11-19 2015-05-28 Siga Technologies, Inc. Rehydration of micronized tecovirimat monohydrate
EP3197435A1 (en) * 2014-09-26 2017-08-02 Millendo Therapeutics, Inc. Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
CA3013937A1 (en) 2016-02-16 2017-08-24 Siga Technologies, Inc. St-246 (tecovirimat monohydrate) suspension formulations
JP7145844B2 (ja) 2017-03-31 2022-10-03 大阪瓦斯株式会社 電気化学素子、電気化学モジュール、固体酸化物形燃料電池、および製造方法
RU2716709C1 (ru) * 2019-08-20 2020-03-16 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Пероральная лекарственная форма препарата в капсулах для лечения и профилактики заболеваний, вызываемых ортопоксвирусами
WO2023080188A1 (ja) * 2021-11-04 2023-05-11 興和株式会社 カプセル剤
WO2023080189A1 (ja) * 2021-11-04 2023-05-11 興和株式会社 医薬品

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670901A1 (de) 1967-08-09 1971-03-18 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US4173646A (en) 1974-10-04 1979-11-06 Merck & Co., Inc. Tricyclicdicarboximides
US4061763A (en) 1975-05-09 1977-12-06 Merck & Co., Inc. Tricyclicdicarboximides
US5068356A (en) 1990-02-20 1991-11-26 Atochem North America, Inc. Hindered phenolic n-(amido)imides
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7125565B2 (en) 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2004112718A2 (en) * 2003-06-20 2004-12-29 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7687641B2 (en) * 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
AU2007351866C1 (en) * 2003-06-20 2013-07-25 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
EP1698349A4 (en) 2003-12-25 2009-12-16 Takeda Pharmaceutical PROCESS FOR IMPROVING THE SUITABILITY FOR GRANULATION
WO2006061364A1 (en) * 2004-12-09 2006-06-15 Zach System S.P.A. Process for the preparation of carvedilol and its enantiomers
EP1868628B1 (en) 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US7872037B2 (en) 2006-03-02 2011-01-18 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
CN101445478B (zh) 2008-08-22 2011-04-06 中国人民解放军军事医学科学院生物工程研究所 含一个结晶水的化合物st-246及其晶体与制备方法
RU2412160C1 (ru) * 2009-09-25 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) 7-[n'-(4-трифторметилбензоил)-гидразинокарбонил]-трицикло[3.2.2.02,4]нон-8-ен-6-карбоновая кислота, обладающая противовирусной активностью
DK2549871T3 (en) * 2010-03-23 2018-12-10 Siga Tech Inc Polymorphic form ST-246 and processes for its preparation

Also Published As

Publication number Publication date
US20210137885A1 (en) 2021-05-13
EP2549871B1 (en) 2018-08-22
JP2018012735A (ja) 2018-01-25
US10933050B2 (en) 2021-03-02
CN103068232A (zh) 2013-04-24
CA2793533C (en) 2019-02-26
BR112012023743A2 (pt) 2015-09-15
KR20160062208A (ko) 2016-06-01
SG184201A1 (en) 2012-10-30
US9744154B2 (en) 2017-08-29
BR112012023743B1 (pt) 2020-02-18
CN103068232B (zh) 2015-08-26
CA3030671A1 (en) 2011-09-29
KR20170102070A (ko) 2017-09-06
FR22C1023I1 (fr) 2022-07-22
US20180311213A1 (en) 2018-11-01
NZ602578A (en) 2014-08-29
KR20150092354A (ko) 2015-08-12
EP2549871A1 (en) 2013-01-30
DK2549871T3 (en) 2018-12-10
RU2012144818A (ru) 2014-04-27
AP2012006514A0 (en) 2012-10-31
AU2011232551B2 (en) 2014-11-13
US9339466B2 (en) 2016-05-17
PE20170944A1 (es) 2017-07-13
PE20130212A1 (es) 2013-03-09
CL2012002621A1 (es) 2013-10-11
CN105175311A (zh) 2015-12-23
US20190343799A1 (en) 2019-11-14
US20160107993A1 (en) 2016-04-21
RU2015146899A (ru) 2019-01-11
FR22C1023I2 (fr) 2024-02-16
JP2013522371A (ja) 2013-06-13
WO2011119698A9 (en) 2013-01-31
KR20150011016A (ko) 2015-01-29
KR20130018271A (ko) 2013-02-20
IL258239A (en) 2018-05-31
EP2549871A4 (en) 2016-03-09
IL241731A0 (en) 2015-11-30
CA2793533A1 (en) 2011-09-29
KR20160028489A (ko) 2016-03-11
US20110236434A1 (en) 2011-09-29
MX2012010859A (es) 2013-04-29
CN105111130A (zh) 2015-12-02
RU2578606C2 (ru) 2016-03-27
US11890270B2 (en) 2024-02-06
ZA201207141B (en) 2016-06-29
US10045964B2 (en) 2018-08-14
CN105111131A (zh) 2015-12-02
MX361428B (es) 2018-12-06
AU2011232551A1 (en) 2012-10-18
AP3221A (en) 2015-04-30
JP2016040323A (ja) 2016-03-24
US20180193308A1 (en) 2018-07-12
IL221991B (en) 2019-06-30
JP6018041B2 (ja) 2016-11-02
WO2011119698A1 (en) 2011-09-29
US10406137B2 (en) 2019-09-10
IL241730A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
IL258239A (en) and st–methods producing polymorphs of 246 for their preparation
HK1178149A1 (zh) 吡唑- -基-雜環基-甲酰胺化合物及其使用方法
PT2539136T (pt) Poste de barreira e método de fabrico do mesmo
IL226477A (en) Salts and polymorphic forms of Aptinib
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
EP2603201A4 (en) LIPOSOME COMPOSITIONS AND USE METHOD THEREFOR
EP2657188A4 (en) FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
EP2548859A4 (en) PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF
GB201009936D0 (en) Method of screening people
IL256026B (en) Treatment methods
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
IL229968A0 (en) Tetrazolyloxy derivatives and methods for their production
EP2611791A4 (en) OLIGOOXOPIPERAZINES AND METHODS FOR THEIR PREPARATION AND USE
EP2573071A4 (en) PROCESS FOR THE PREPARATION OF (S) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE
IL222360A0 (en) Method of vaccination
EP2670245A4 (en) ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM
GB201115521D0 (en) Colorant-polyesters and methods of producing colorant-polyesters
EP2536705A4 (en) POLYMORPHIC FORMS OF LUBIPROSTON
EP2592997A4 (en) FORCE-FORCE SPECTROMETER AND METHODS OF USE
EP2578564A4 (en) INTERMEDIATE PRODUCTS OF LYCOPEN AND MANUFACTURING PROCESS FOR THESE INTERMEDIATE PRODUCTS